Citations

Clear

4847 citation(s) found for "Tu, Eric".

De novo and inherited monoallelic variants in TUBA4A cause ataxia and spasticity
Benkirane, Mehdi , Bonhomme, Marion , Morsy, Heba , Marelli, Cécilia , Chaussenot, Annabelle , Smedley, Damian , Cipriani, Valentina , Sainte-Agathe, Jean-Madeleine de, Ding, Can, Larrieu, Lise, Vestito, Letizia , Margot, Henri , Ramond, Francis , Castrioto, Anna , Sansa, Emna, Haetty, Aline, Bergougnoux, Anne , Pointaux, Morgane, Ardouin, Olivier , Goethem, Charles Van , Vincent, Marie‐Claire, Hadjivassiliou, Marios , Cossée, Mireille , Rouaud, Tiphaine , Bartsch, Oliver , Wierenga, Klaas J. , Klee, Eric W. , Vandrovcová, Jana , Debant, Anne , Koenig, Michel, Smedley, Damian , Baux, David , Verheijen, Jan , Freeman, William D , Klee, Eric W , Vandrovcova, Jana , Houlden, Henry , Safgren, Stephanie L. , Agathe, Jean‐Madeleine de Sainte , Ding, Can, Lesca, Gaëtan , Sansa, Emna, Giunti, Paola , Freeman, William D. , Houlden, Henry , Koenig, Michel

Mayo Clinic

Brain | June 14, 2024 | Volume: 147 | Issue: 11 | Pages: 3681-3689

10.1093/brain/awae193 | PMID 38884572 Get It

Abstract Alpha-tubulin 4A encoding gene (TUBA4A) has been associated with familial amyotrophic lateral sclerosis and frontotemporal dementia, based on identification of likely pathogenic variants in patients from distinct amyotrophic lateral sclerosis and frontotemporal dementia cohorts. By screening a multicentric French cohort of 448 unrelated probands presenting with cerebellar ataxia, we identified ultra-rare TUBA4A missense variants, all being absent from public databases and predicted pathogenic by multiple in silico tools. In addition, gene burden analyses in the 100 000 Genomes project (100KGP) showed enrichment of TUBA4A rare variants in the inherited ataxia group compared to controls [odds ratio: 57.0847 (10.2−576.7); P = 4.02 ×10−7]. Taken together, we report 12 patients presenting with spasticity and/or cerebellar ataxia and harbouring a predicted pathogenic TUBA4A missense mutation, including five confirmed de novo cases and a mutation previously reported in a large family presenting with spastic ataxia. Cultured fibroblasts from three patients harbouring distinct TUBA4A missense showed significant alterations in microtubule organization and dynamics, providing insight of TUBA4A variants pathogenicity. Our data confirm the identification of a hereditary spastic ataxia disease gene with variable age of onset, expanding the clinical spectrum of TUBA4A associated phenotypes.
Single cell multiomic analyses reveal divergent effects of DNMT3A and TET2 mutant clonal hematopoiesis in inflammatory response
Binder, Moritz , Lasho, Terra, Geyer, Susan M. , Finke, Christy M. , Mangaonkar, Abhishek A. , Simon, Vernadette, Rohakthar, Fariborz Rakhshan, Munankarmy, Amik, Schwager, Susan M., Harrington, Jonathan J. , Snyder, Melissa R. , Wieben, Eric D. , Patnaik, Mrinal M. , Binder, Moritz , Ismail, Wazim Mohammed , Fernandez, Jenna , Kim, Minsuk , Mazzone, Amelia , Lee, Jeong‐Heon , Wang, Liguo , Kim, Kwan‐Hyun , Munankarmy, Amik , Byeon, Seul Kee , Robertson, Keith D. , Pandey, Akhilesh , Chia, Nicholas , Gaspar‐Maia, Alexandre

Mayo Clinic

No container title available | June 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4481664/v1 Get It

Abstract Background DNMT3A and TET2 are epigenetic regulator genes commonly mutated in age-related clonal hematopoiesis (CH). Despite having opposing epigenetic functions, these mutations are associated with increased all-cause mortality and a low risk for progression to hematological neoplasms. While individual impacts on the epigenome have been described using different model systems, the phenotypic complexity in humans remains to be elucidated. Results Here we make use of a natural inflammatory response occurring during coronavirus disease 2019 (COVID-19), to understand the association of these mutations with inflammatory morbidity and mortality. We demonstrate the age-independent, negative impact of DNMT3A mutant CH on COVID-19-related cytokine release severity and mortality. Using single cell proteogenomics we show that DNMT3A mutations involve myeloid and lymphoid cells. Using single cell multiomics sequencing, we identify cell-specific gene expression changes associated with DNMT3A mutations, along with significant epigenomic deregulation affecting enhancer accessibility, resulting in overexpression of IL32, a proinflammatory cytokine that can result in inflammasome activation in monocytes and macrophages. Finally, we show with single cell resolution that the loss of function of DNMT3A is directly associated with increased chromatin accessibility in mutant cells. Conclusions We demonstrate the negative prognostic impact of DNMT3Amt CH on COVID-19 related inflammatory morbidity and mortality. DNMT3Amt CH involves myeloid and lymphoid cells and in the context of COVID-19, was associated with inflammatory transcriptional priming, resulting in overexpression of IL32. This overexpression was secondary to increased chromatic accessibility, specific to DNMT3Amt CH cells. DNMT3Amt CH can serve as a potential biomarker for adverse inflammatory outcomes.
Impact of cancer screening results on patient-reported outcomes (PRO) and behavioral intentions.
Patrick, Donald L. , Mulnick, Sarah, Samuelson, Ashley, Cong, Ze, Reid, Robert , Lopatin, Margarita , Fung, Eric T. , Dilaveri, Christina A. , McDonnell, Charles H. , Ross, Melissa , Chung, Karen , Klein, Eric A. , Marinac, Catherine R.

Mayo Clinic

Journal of Clinical Oncology | June 12, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 10608-10608

10.1200/jco.2024.42.16_suppl.10608 Get It

10608 Background: Cancer is one of the most feared diseases. Multi-cancer early detection (MCED) tests have the potential to expand the number of cancers that are detected at earlier stages, which could result in better clinical outcomes. However, behavioral impacts based on MCED test results could affect the utility and value of these tests. Methods: Two independent data sources evaluated the impact of MCED test results on behavioral intentions and perceptions: a survey of the general population and PRO in an MCED clinical trial. A web-based, 30-minute survey of the US general population was used to ascertain attitudes toward a hypothetical MCED test. Eligible respondents were adults aged 40-80 years without a cancer diagnosis in the previous 5 years. The survey assessed the perceived value of negative results (ie, no cancer signal detected [NCSD]) and the projected impact on post-test behaviors. The prospective PATHFINDER study (NCT04241796) of adults aged ≥50 years who underwent MCED cancer screening included PRO assessments. Post-test assessments included: "I am feeling relieved about my test result" from the adapted MICRA and “How likely are you to follow your healthcare provider’s cancer screening recommendations.” The consistency of sentiment after an NCSD MCED result from the online survey and clinical study was assessed. Results: Of the 1073 online survey respondents, 53% were female, 77% White, 14% Black/African American, and 13% Hispanic. Mean age was 58 years. The most common anticipated emotional impacts were relief (84%), happiness (72%), and confidence (69%). Respondents (66-70%) reported they would expect less worry, fear, stress, and anxiety after an NCSD MCED result. The majority (73%) reported they would maintain or improve health behaviors after an NCSD result. NCSD results were projected to lead to an increase in health-related behaviors, including adherence to recommended cancer screening (98%; 68% increase, 30% maintain current level) and regular doctor visits (46%). Of the 6529 PATHFINDER study participants who received NCSD results, 64% were female, 92% White. Mean age was 63 years. 80% of participants (n = 4685/5865) with NCSD felt relief "sometimes" or "often" after their MCED test result. Over 95% of participants (n = 5637/5863) with NCSD indicated they were "likely" or "very likely" to adhere to cancer screening recommendations in the future. Conclusions: Results from a general population survey and a prospective clinical study indicate that an NCSD result may be associated with positive cancer screening intentions and other preventive healthcare behaviors. An NCSD result may also positively impact psychological and emotional health. While these findings suggest that an NCSD result may provide additional value beyond traditional clinical benefits associated with cancer screening, future research is needed to delineate the behavioral impact following MCED screening. Clinical trial information: NCT04241796 .
A reproducible method for evaluating the degree and direction of overstuffing of the humeral head component in anatomic total shoulder arthroplasty
Panther, Eric , Hao, Kévin A. , Patrick, Matthew , King, Joseph J. , Wright, Thomas W. , Struk, Aimee M., Wright, Jonathan O. , Panther, Eric J , Schoch, Bradley S , King, Joseph J , Wright, Jonathan O , Hao, Kevin A , Schoch, Bradley S.

Mayo Clinic

Shoulder & Elbow | June 12, 2024 | Volume: 17 | Issue: 3 | Pages: 282-287

10.1177/17585732241258069 | PMID 39552655 Get It

Background Improper sizing of the humeral head component in anatomic total shoulder arthroplasty (ATSA) can overstuff the joint, potentially compromising outcomes. The purpose of this study was to validate a novel method of evaluating glenohumeral joint overstuffing in which superoinferior and mediolateral overstuffing can be evaluated independently relative to the native humeral anatomy. Methods We identified 25 patients who underwent ATSA and the best Grashey radiograph taken within 1 year of follow-up was assessed using our proposed technique. First, a circle overlaying the implanted humeral head was made. Then, Iannotti's Perfect Circle (IPC) was drawn as originally described. Measurements of superior and medial overstuffing were made using our proposed axes. Inter-rater reliability was assessed by computing interclass correlation coefficients (ICC) using a one-way model. Measurements were summarized as the mean and range, with positive values denoting overstuffing. Results The inter-rater reliability for all measurements was excellent (ICC > 0.9). Compared to our method, the IPC method would have missed 77% of overstuffed cases. Conclusion We present a reproducible method to assess glenohumeral joint overstuffing in ATSA. This technique addresses limitations of other methods that underestimate overstuffing. Further study is needed to establish a clinically significant value of overstuffing based on the proposed method.
Increasing hub disruption parallels dementia severity in autosomal dominant Alzheimer’s disease
Tu, Jiaxin Cindy , Millar, Peter R , Strain, Jeremy F. , Eck, Andrew, Adeyemo, Babatunde, Daniels, Alisha , Huey, Edward D. , Day, Gregory S. , Hassenstab, Jason , Méndez, Patricio Chrem, Perrin, Richard J. , Jack, Clifford R. , Betzel, Richard F. , Wheelock, Muriah D. , Network, the Dominantly Inherited Alzheimer, Wheelock, Muriah D , Jack, Clifford R , Day, Gregory S , Hassenstab, Jason , Daniels, Alisha, Karch, Celeste M. , Huey, Edward D., McDade, Eric, Igor, Yakushev, Hassenstab, Jason, Morris, John, Llibre‐Guerra, Jorge J. , Ibanez, Laura , Jucker, Mathias , Bateman, Randall J. , Benzinger, Tammie L.S. , Ances, Beau M. , Eggebrecht, Adam T. , Gordon, Brian A. , (DIAN), The Dominantly Inherited Alzheimer Network

Mayo Clinic

Network Neuroscience | June 11, 2024 | Volume: 8 | Issue: 4 | Pages: 1265-1290

10.1162/netn_a_00395 | PMID 39735502 Get It

Abstract Hub regions in the brain, recognized for their roles in ensuring efficient information transfer, are vulnerable to pathological alterations in neurodegenerative conditions, including Alzheimer’s disease (AD). Computational simulations and animal experiments have hinted at the theory of activity-dependent degeneration as the cause of this hub vulnerability. However, two critical issues remain unresolved. First, past research has not clearly distinguished between two scenarios: hub regions facing a higher risk of connectivity disruption (targeted attack) and all regions having an equal risk (random attack). Second, human studies offering support for activity-dependent explanations remain scarce. We refined the hub disruption index to demonstrate a hub disruption pattern in functional connectivity in autosomal dominant AD that aligned with targeted attacks. This hub disruption is detectable even in preclinical stages, 12 years before the expected symptom onset and is amplified alongside symptomatic progression. Moreover, hub disruption was primarily tied to regional differences in global connectivity and sequentially followed changes observed in amyloid-beta positron emission tomography cortical markers, consistent with the activity-dependent degeneration explanation. Taken together, our findings deepen the understanding of brain network organization in neurodegenerative diseases and could be instrumental in refining diagnostic and targeted therapeutic strategies for AD in the future.
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Adam, Mohamed A. , Chang, George J. , Chen, Yi-Jen, Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Haste, Paul, Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Joseph, Nora, Kirilcuk, Natalie, Krishnamurthi, Smitha , Malla, Midhun , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Parikh, Aparna, Patel, Hitendra , Shibata, David , Shogan, Benjamin D. , Skibber, John M., Sofocleous, Constantinos T. , Tavakkoli, Anna , Willett, Christopher G. , Wu, Christina, Gurski, Lisa A., Snedeker, Jenna, Jones, Frankie, Meyerhardt, Jeffrey A , Venook, Alan P. , Chen, Yi‐Jen , Ciombor, Kristen K. , Cohen, Stacey A. , Hussan, Hisham , Miller, Eric D. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 11, 2024 | Volume: 22 | Issue: 2D | Pages: No page available

10.6004/jnccn.2024.0029 | PMID 38862008 Get It

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States. Management of disseminated metastatic CRC involves various active drugs, either in combination or as single agents. The choice of therapy is based on consideration of the goals of therapy, the type and timing of prior therapy, the mutational profile of the tumor, and the differing toxicity profiles of the constituent drugs. This manuscript summarizes the data supporting the systemic therapy options recommended for metastatic CRC in the NCCN Guidelines for Colon Cancer.
Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study
Keaveny, Tony M. , Adams, Annette L. , Orwoll, Eric , Khosla, Sundeep , Siris, Ethel S. , McClung, Michael R. , Bouxsein, Mary , Fatemi, Shireen, Lee, David C. , Kopperdahl, David L. , Orwoll, Eric S , Bouxsein, Mary L , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | June 10, 2024 | Volume: 39 | Issue: 10 | Pages: 1424-1433

10.1093/jbmr/zjae090 | PMID 38861422 Get It

Abstract Randomized trials have not been performed, and may never be, to determine if osteoporosis treatment prevents hip fracture in men. Addressing that evidence gap, we analyzed data from an observational study of new hip fractures in a large integrated healthcare system to compare the reduction in hip fractures associated with standard-of-care osteoporosis treatment in men versus women. Sampling from 271,389 patients aged ≥ 65 who had a hip-containing CT scan during care between 2005 and 2018, we selected all who subsequently had a first hip fracture (cases) after the CT scan (start of observation) and a sex-matched equal number of randomly selected patients. From those, we analyzed all who tested positive for osteoporosis (DXA-equivalent hip BMD T-score ≤ −2.5, measured from the CT scan using VirtuOst). We defined “treated” as at least six months of any osteoporosis medication by prescription fill data during follow-up; “not-treated” was no prescription fill. Sex-specific odds ratios of hip fracture for treated vs not-treated patients were calculated by logistic regression; adjustments included age, BMD T-score, BMD-treatment interaction, BMD, race/ethnicity, and seven baseline clinical risk factors. At two-year follow-up, 33.9% of the women (750/2,211 patients) and 24.0% of the men (175/728 patients) were treated primarily with alendronate; 51.3% and 66.3%, respectively, were not-treated; and 721 and 269, respectively, had a first hip fracture since the CT scan. Odds ratio of hip fracture for treated vs not-treated was 0.26 (95% confidence interval: 0.21–0.33) for women and 0.21 (0.13–0.34) for men; the ratio of these odds ratios (men:women) was 0.81 (0.47–1.37), indicating no significant sex effect. Various sensitivity and stratified analyses confirmed these trends, including results at five-year follow-up. Given these results and considering the relevant literature, we conclude that osteoporosis treatment prevents hip fracture similarly in both sexes.
The expanding clinical and genetic spectrum of DYNC1H1 -related disorders
Möller, Birk , Becker, Lena‐Luise , Saffari, Afshin , Afenjar, Alexandra , Coci, Emanuele G. , Williamson, Rachel, Ward‐Melver, Catherine, Gibaud, Marc, Libá, Zuzana , Vlčková, Markéta , William, N , Klee, Eric W. , Gavrilova, Ralitza H. , Capri, Yline, Scavina, Mena , Körner, Robert Walter , Valivullah, Zaheer M. , Weiß, Claudia , Möller, Greta Marit, Frazier, Zoë, Roberts, Amy L. , Gener, Blanca , Scala, Marcello , Striano, Pasquale, Thiel, Moritz , Sinnema, Margje, Kamsteeg, Erik‐Jan , Donkervoort, Sandra, Duboc, Véronique , Zaafrane‐Khachnaoui, Khaoula , Elkhateeb, Nour , Margot, Henri , Isidor, Bertrand, Keren, Boris, Küsters, Benno , Sveden, Abigail , Nicolai, Joost , Dötsch, Jörg , Koy, Anne , Bönnemann, C. , Hagen, Maja von der , Kleist-Retzow, Jürgen‐Christoph von , Voermans, Nicol C, Jungbluth, Heinz , Donkervoort, Sandra , William, Nancy, Klee, Eric W , Thiel, Moritz , Kamsteeg, Erik-Jan , Beggs, Alan H , Koy, Anne , Dafsari, Hormos Salimi , Donkervoort, Sandra , Scala, Marcello , Gibaud, Marc , Sedláčková, Lucie , Laššuthová, Petra , Lévy, Jonathan , Capri, Yline , Roberts, Amy, Zara, Federico , Duboc, Veronique, Selim, Laila , Marin, Victor, Bénéteau, Claire , Isidor, Bertrand , Cogné, Benjamin , Keren, Boris , Beggs, Alan H. , Chopra, Maya , Genetti, Casie A. , Dafsari, Hormos Salimi

Mayo Clinic

Brain | June 6, 2024 | Volume: 148 | Issue: 2 | Pages: 597-612

10.1093/brain/awae183 | PMID 38848546 Get It

Abstract Intracellular trafficking involves an intricate machinery of motor complexes, including the dynein complex, to shuttle cargo for autophagolysosomal degradation. Deficiency in dynein axonemal chains, as well as cytoplasmic light and intermediate chains, have been linked with ciliary dyskinesia and skeletal dysplasia. The cytoplasmic dynein 1 heavy chain protein (DYNC1H1) serves as a core complex for retrograde trafficking in neuronal axons. Dominant pathogenic variants in DYNC1H1 have been previously implicated in peripheral neuromuscular disorders (NMD) and neurodevelopmental disorders (NDD). As heavy-chain dynein is ubiquitously expressed, the apparent selectivity of heavy chain dyneinopathy for motor neuronal phenotypes remains currently unaccounted for. Here, we aimed to evaluate the full DYNC1H1-related clinical, molecular and imaging spectrum, including multisystem features and novel phenotypes presenting throughout life. We identified 47 cases from 43 families with pathogenic heterozygous variants in DYNC1H1 (aged 0–59 years) and collected phenotypic data via a comprehensive standardized survey and clinical follow-up appointments. Most patients presented with divergent and previously unrecognized neurological and multisystem features, leading to significant delays in genetic testing and establishing the correct diagnosis. Neurological phenotypes include novel autonomic features, previously rarely described behavioral disorders, movement disorders and periventricular lesions. Sensory neuropathy was identified in nine patients (median age of onset 10.6 years), of which five were only diagnosed after the second decade of life, and three had a progressive age-dependent sensory neuropathy. Novel multisystem features included primary immunodeficiency, bilateral sensorineural hearing loss, organ anomalies and skeletal manifestations, resembling the phenotypic spectrum of other dyneinopathies. We also identified an age-dependent biphasic disease course with developmental regression in the first decade and, following a period of stability, neurodegenerative progression after the second decade of life. Of note, we observed several cases in whom neurodegeneration appeared to be prompted by intercurrent systemic infections with double-stranded DNA viruses (Herpesviridae) or single-stranded RNA viruses (Ross River fever, SARS-CoV-2). Moreover, the disease course appeared to be exacerbated by viral infections regardless of age and/or severity of neurodevelopmental disorder manifestations, indicating a role of dynein in anti-viral immunity and neuronal health. In summary, our findings expand the clinical, imaging and molecular spectrum of pathogenic DYNC1H1 variants beyond motor neuropathy disorders and suggest a life-long continuum and age-related progression due to deficient intracellular trafficking. This study will facilitate early diagnosis and improve counselling and health surveillance of affected patients.
Association of Ground-Glass Opacities with Systemic Inflammation and Progression of Emphysema
Fortis, Spyridon , Guo, Junfeng , Chaudhary, Muhammad F. A. , Newell, John D. , Gerard, Sarah E. , Han, MeiLan K., Kazerooni, Ella A. , Bodduluri, Sandeep, Paine, Robert , Awan, Hira A. , Schroeder, Joyce , Gravens‐Mueller, Lisa, Ortega, Victor E. , Anderson, Wayne H. , Cooper, Christopher B. , Woodruff, Prescott G. , Bhatt, Surya P. , Hoffman, Eric A. , Comellas, Alejandro P. , Bowler, Russell P , Hoffman, Eric A , Comellas, Alejandro P , Fortis, Spyridon , Bhatt, Surya P , Nagpal, Prashant , Han, MeiLan King , Martínez, Fernando J. , Barjaktarević, Igor , Barr, R. Graham , Bodduluri, Sandeep , Couper, David , Bowler, Russell P. , Reinhardt, Joseph M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 6, 2024 | Volume: 210 | Issue: 12 | Pages: 1432-1440

10.1164/rccm.202310-1825oc | PMID 38843116 Get It

Abstract Rationale Ground-glass opacities (GGOs) in the absence of interstitial lung disease are understudied. Objectives To assess the association of GGOs with white blood cells (WBCs) and progression of quantified chest computed tomography emphysema. Methods We analyzed data of participants in the SPIROMICS study (Subpopulations and Intermediate Outcome Measures in COPD Study). Chest radiologists and pulmonologists labeled regions of the lung as GGOs, and the adaptive multiple feature method (AMFM) trained the computer to assign those labels to image voxels and quantify the volume of the lung with GGOs (%GGOAMFM). We used multivariable linear regression, zero-inflated negative binomial, and proportional hazards regression models to assess the association of %GGOAMFM with WBCs, changes in percentage emphysema, and clinical outcomes. Measurements and Main Results Among 2,714 participants, 1,680 had chronic obstructive pulmonary disease (COPD) and 1,034 had normal spirometry. Among participants with COPD, on the basis of multivariable analysis, current smoking and chronic productive cough were associated with higher %GGOAMFM. Higher %GGOAMFM was cross-sectionally associated with higher WBC and neutrophil concentrations. Higher %GGOAMFM per interquartile range at visit 1 (baseline) was associated with an increase in emphysema at 1-year follow-up visit by 11.7% (relative increase; 95% confidence interval, 7.5–16.1%; P < 0.001). We found no association between %GGOAMFM and 1-year FEV1 decline, but %GGOAMFM was associated with exacerbations and all-cause mortality during a median follow-up of 1,544 days (interquartile interval, 1,118–2,059). Among normal spirometry participants, we found similar results, except that %GGOAMFM was associated with progression to COPD at 1-year follow-up. Conclusions Our findings suggest that GGOAMFM is associated with increased systemic inflammation and emphysema progression.